NCT06191328View on ClinicalTrials.gov

A Prospective, Open, Self-controlled Study of the Effects of Chiglitazar Sodium on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus (T2DM)

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions
Diabetes
Interventions
DRUG

Chiglitazar sodium

In patients with type 2 diabetes mellitus (T2DM), on the basis of one or two oral hypoglycemic agents combination with Chiglitazar sodium.

Trial Locations (1)

200080

Shanghai First People's Hospital, Shanghai

All Listed Sponsors
lead

Yufan Wang

OTHER

NCT06191328 - A Prospective, Open, Self-controlled Study of the Effects of Chiglitazar Sodium on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter | Biotech Hunter